PET scans show effectiveness of thyroid drug

Share this content:

Positron emission tomography (PET) can indicate how well a thyroid tumor is responding to treatment with vandetanib. This agent, which is currently being tested in clinical trials, inhibits the function of the rearranged-during-transfection protein (RET) protooncogene and other protein kinases involved in the development and progression of cancer.

The effectiveness of vandetanib is usually measured by changes in tumor size.  Based on the agent's effect on many intracellular metabolic pathways, however, a team of nuclear medicine experts hypothesized that metabolic imaging could be a useful—and noninvasive—method for detecting early response to vandetanib.

The researchers first achieved metabolic imaging of the agent in vitro, through transcriptional profiling and radiotracer uptake studies of medullary thyroid cancer cells. Mice were then injected with the cancerous cells for in vivo testing. Small-animal PET and computed tomography (CT) imaging reproduced the in vitro findings of metabolic activity after 3 days.

Eventually, PET scans were used to detect a human patient's metabolic response to vandetanib at 12 and 24 weeks after treatment.

“Our results suggest that PET may be useful for identifying patients who respond to vandetanib early in the course of treatment,” wrote the investigators in The Journal of Nuclear Medicine (2011;52[2];231-240).

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs